Keith W Pratz/X
Nov 8, 2024, 14:30
Keith W Pratz: The utility of post remission use of GCSF in the VIALE-A trial
Keith W Pratz, Director of Leukemia, Hospital of University of Pennsylvania Philadelphia, shared his recent article on X:
“Happy to share our report on the utility of post remission use of GCSF in the VIALE-A trial.
In the CR/CRi patients given GCSF, OS was 30.8 m vs 21.1 mo and MRD neg response 51% vs 33%.
Important data to feel safe to use GCSF with blast clearance.”
Authors: Courtney D. DiNardo, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 14:05
Nov 13, 2024, 12:13
Nov 13, 2024, 11:52
Nov 13, 2024, 11:48
Nov 13, 2024, 11:44
Nov 13, 2024, 11:39
Nov 13, 2024, 11:30
Nov 13, 2024, 11:25
Nov 13, 2024, 11:10